Prevention of VTE in Orthopedic Surgery

Prevention of VTE: Orthopedic Surgery

ACCP Prevention of VTE in Orthopedic Surgery GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/92469

Contents of this Issue

Navigation

Page 4 of 5

Table 1. Agents Recommended for Deep Vein Thrombosisa Agent (Brand) Warfarin (Coumadin®, Jantoven® ) Heparins Dalteparin (LMWH) (Fragmin® Enoxaparin (LMWH) (Clexane® Heparin (UFH) Thrombin IIa Inhibitor Dabigatranc (Pradaxa® Factor Xa Inhibitors Apixaband (Eliquis® ) Fondaparinux (Arixtra® Rivaroxaban (Xarelto® ) a See Prescribing Information for details. b Adjust to international normalized ratio. c Not FDA-approved for VTE prevention ) ) ) ) Dose POb Prophylaxis: 5,000 units subcut daily 40 mg subcut daily or 30 mg subcut twice daily 5,000 units subcut q8h ClCr ClCr > 30 mL/min: 220 mg PO daily 15-30 mL/min: 150 mg PO daily 2.5 mg PO bid Prophylaxis: 2.5 mg subcut daily Prophylaxis: 10 mg PO daily d Apixaban was not FDA approved in the United States at the time of the guideline publication.

Articles in this issue

Archives of this issue

view archives of Prevention of VTE in Orthopedic Surgery - Prevention of VTE: Orthopedic Surgery